Ernexa Therapeutics Inc.
13F holders, Q2 2025 (June 30)12holders
$1.84avg. 13F price*
At the end of Q2 2025, 12 institutions reported holding Ernexa Therapeutics Inc. in their 13F filings. The largest holders were Geode Capital Management, LLC ($37K), Corient Private Wealth LP ($32K) and Sippican Capital Advisors ($18K).
- Company
- Ernexa Therapeutics Inc.
- CUSIP
- 114082308
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1K |
| Exits | 0 | $0 |
Ownership 12 holders
| Geode Capital Management, LLC | 0.00% | Add +2.7% | 20,075 | $37K |
| Corient Private Wealth LP | 0.00% | No change | 17,523 | $32K |
| Sippican Capital Advisors | 0.01% | Add +87.5% | 10,000 | $18K |
| BlackRock, Inc. | 0.00% | No change | 820 | $2K |
| Morgan Stanley | 0.00% | New | 554 | $1K |
| UBS Group AG | 0.00% | Reduce -34.1% | 548 | $1K |
| Assetmark, Inc. | 0.00% | Reduce -0.3% | 133 | $245 |
| EverSource Wealth Advisors, LLC | 0.00% | Reduce -0.8% | 116 | $213 |
| Bank of America Corp. | 0.00% | Add +1.9% | 21 | $39 |
| BNP Paribas Financial Markets | 0.00% | Add +7.1% | 10 | $18 |
| Montag A & Associates Inc. | 0.00% | Reduce -14.9% | 8 | $15 |
| Activest Wealth Management | 0.00% | Reduce -10.0% | 3 | $6 |
"% of holder's portfolio" is ERNEXA THERAPEUTICS INC's weight in each manager's 13F, not the share of Ernexa Therapeutics Inc. the manager owns.